1030367-80-6

Basic information

• Product Name: tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane
• Synonyms: tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane
• CAS NO: 1030367-80-6
• Molecular Weight: 488.689
• Mol File: 1030367-80-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane(1030367-80-6)
• EPA Substance Registry System: tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane(1030367-80-6)

Safety Data

• Hazardous Substances Data: 1030367-80-6(Hazardous Substances Data)

Upstream product

• 457889-46-2 (4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanol 
• 454464-38-1 4-Chloromethyl-4'-trifluoromethyl-biphenyl 
• 1030367-79-3 2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1030367-84-0 C₃₄H₃₅F₅OSSi 
• 1030367-81-7 tert-butyl dimethyl(2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenoxy)silane 
• 1030367-85-1 C₃₄H₃₅Cl₂F₃OSSi 
• 1030367-82-8 C₃₄H₃₅ClF₄OSSi 
• 1030367-83-9 C₃₄H₃₄F₆OSSi 
• 1030367-86-2 C₃₅H₃₅F₇OSSi 
• 1030367-87-3 2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenol 
• 1030367-89-5 C₃₂H₂₉F₃O₃S 
• 1030367-91-9 C₃₄H₃₃F₃O₃S 
• 1030367-93-1 C₃₄H₃₃F₃O₃S 
• 1030367-94-2 C₃₅H₃₅F₃O₃S 
• 1030367-96-4 2-(2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenoxy)acetic acid 
• 1030367-98-6 C₃₃H₂₉F₃O₃S 
• 1030368-00-3 C₃₀H₂₄F₃O₃S^(1-)*K⁽¹⁺⁾ 

Relevant articles and documents

Synthesis and evaluation of an orally available “Y”-shaped biaryl peroxisome proliferator-activated receptor δ agonist

In this study, we designed and synthesized several novel “Y”-shaped biaryl PPARδ agonists. Structure-activity relationship (SAR) studies demonstrated that compound 3a was the most active agonist with an EC50 of 2.6 nM. We also synthesized and evaluated enantiospecific R and S isomers of compound 3a to confirm that R isomer (EC50 = 0.7 nM) shows much more potent activity than S isomer (EC50 = 6.1 nM). Molecular docking studies between the PPAR ligand binding domain and enantiospecific R and S isomers of compound 3a were performed. In vitro absorption, distribution, metabolism, excretion, and toxicity (ADMET) and in vivo PK profiles show that compound 3a possesses superior drug-like properties including good bioavailability. Our overall results clearly demonstrate that this orally administrable PPARδ agonist 3a is a viable drug candidate for the treatment of various PPARδ-related disorders.

ARYL COMPOUNDS AS PPAR LIGANDS AND THEIR USE

The present invention relates to a compound as a peroxisome proliferator activated receptor (PPAR) activator and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, a cosmetic composition, a muscle strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.